Joel S. Parker

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Associations of the HER2DX Genomic Test with Biological and Pathological Features in HER2-positive Breast Cancer.

  UNC Libraries · 2026-02-13

• Figure 4 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

  2026-02-04

• Data from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

  2026-02-04

• Figure 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

  2026-02-04

• Figure 5 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

  2026-02-04

• Supplementary Data 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

  2026-02-04

• Figure 3 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

  2026-02-04

• Table 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

  2026-02-04

• Figure 2 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

  2026-02-04

• Associations of the HER2DX Genomic Test with Biological and Pathological Features in HER2-positive Breast Cancer.

  Open MIND · 2026-01-01

• Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

  Clinical Cancer Research · 2025-12-01 · 2 citations

• Supplementary Figure S5 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

  2025-11-25

• Supplementary Figure S1 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

  2025-11-25

• Supplementary Table S4 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

  2025-11-25

• Supplementary Table S2 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

  2025-11-25

• Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

  2025-11-25

• Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

  2025-11-25

• Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

  2025-11-25

• Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

  2025-11-25

• Supplementary Figure S4 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

  2025-11-25